YYÜ GCRIS Basic veritabanının içerik oluşturulması ve kurulumu Research Ecosystems (https://www.researchecosystems.com) tarafından devam etmektedir. Bu süreçte gördüğünüz verilerde eksikler olabilir.
 

A Modified Dcf Regimen as Primary Treatment for Patients With Metastatic Gastric Cancer

dc.authorscopusid 43761313900
dc.authorscopusid 26030385100
dc.authorscopusid 55453820600
dc.authorscopusid 55037392900
dc.authorscopusid 58707759000
dc.contributor.author Koca, D.
dc.contributor.author Dogan, E.
dc.contributor.author Yardim, H.
dc.contributor.author Duzen, O.
dc.contributor.author Karaca, S.
dc.date.accessioned 2025-05-10T16:57:23Z
dc.date.available 2025-05-10T16:57:23Z
dc.date.issued 2013
dc.department T.C. Van Yüzüncü Yıl Üniversitesi en_US
dc.department-temp [Koca, D.; Dogan, E.] Van Yuzuncu Yil Univ, Reg Training & Res Hosp, Dept Internal Dis, Div Med Oncol, TR-65001 Suphan Mah, Van, Turkey; [Yardim, H.; Duzen, O.] Van Yuzuncu Yil Univ, Reg Training & Res Hosp, Dept Internal Dis, TR-65001 Suphan Mah, Van, Turkey; [Karaca, S.] Van Yuzuncu Yil Univ, Reg Training & Res Hosp, Dept Radiol, TR-65001 Suphan Mah, Van, Turkey en_US
dc.description.abstract Purpose: To retrospectively assess the efficacy and toxity of a modified docetaxel, cisplatin, fluorouracil (mDCF) regimen as primary treatment in patients with metastatic gastric cancer (MGC). Methods: mDCF included folinic acid 400 mg/m(2) (day 1) + 5-fluorouracil (5-FU) 400 mg/m2 i.v. bolus (day 1) + 5-FU 2400 mg/m2 46-h infusion (days 1 and 2) + docetaxel 60 mg/m2 (day 1) + cisplatin 50 mg/m2 (day 1) and was administered once every two weeks in MGC patients. Results: Eighty-nine patients (median age 59 years, range 31-79) were enrolled. The median number of courses was 6 (range 2-12), and the total number was 492. The median follow-up duration was 8.6 months (range 2-14). Three (3.3%) patients showed complete response, 21 (23.6%) partial response, 36 (40.4%) stable disease, and progression was observed in 29 (32.6%) patients. The median progression-free survival (PFS) rate was 7 months (95% CI 5.7-8.2), and the median overall survival (OS) rate was 11 months (95% CI 9.7-12.2). The most common toxicity was neutropenia, which was observed in 52 (58.4%) patients. Conclusion: mDCF with reduced drug doses, given every two weeks, is a rather efficient regimen for MGC patients. en_US
dc.description.woscitationindex Science Citation Index Expanded
dc.identifier.endpage 384 en_US
dc.identifier.issn 1107-0625
dc.identifier.issn 2241-6293
dc.identifier.issue 2 en_US
dc.identifier.pmid 23818349
dc.identifier.scopus 2-s2.0-84879593007
dc.identifier.scopusquality N/A
dc.identifier.startpage 377 en_US
dc.identifier.uri https://hdl.handle.net/20.500.14720/4017
dc.identifier.volume 18 en_US
dc.identifier.wos WOS:000322750700011
dc.identifier.wosquality N/A
dc.language.iso en en_US
dc.publisher Imprimatur Publications en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Cisplatin en_US
dc.subject Docetaxel en_US
dc.subject Fluorouracil en_US
dc.subject Metastatic Gastric Cancer en_US
dc.subject Modified Dcf en_US
dc.subject Primary Treatment en_US
dc.title A Modified Dcf Regimen as Primary Treatment for Patients With Metastatic Gastric Cancer en_US
dc.type Article en_US

Files